Engineering of IF1 -susceptive bacterial F1 -ATPase. 2024

Yuichiro C Hatasaki, and Ryohei Kobayashi, and Ryo R Watanabe, and Mayu Hara, and Hiroshi Ueno, and Hiroyuki Noji
Department of Applied Chemistry, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.

IF1 , an inhibitor protein of mitochondrial ATP synthase, suppresses ATP hydrolytic activity of F1 . One of the unique features of IF1 is the selective inhibition in mitochondrial F1 (MF1 ); it inhibits catalysis of MF1 but does not affect F1 with bacterial origin despite high sequence homology between MF1 and bacterial F1 . Here, we aimed to engineer thermophilic Bacillus F1 (TF1 ) to confer the susceptibility to IF1 for elucidating the molecular mechanism of selective inhibition of IF1 . We first examined the IF1 -susceptibility of hybrid F1 s, composed of each subunit originating from bovine MF1 (bMF1 ) or TF1 . It was clearly shown that only the hybrid with the β subunit of mitochondrial origin has the IF1 -susceptibility. Based on structural analysis and sequence alignment of bMF1 and TF1 , the five non-conserved residues on the C-terminus of the β subunit were identified as the candidate responsible for the IF1 -susceptibility. These residues in TF1 were substituted with the bMF1 residues. The resultant mutant TF1 showed evident IF1 -susceptibility. Reversely, we examined the bMF1 mutant with TF1 residues at the corresponding sites, which showed significant suppression of IF1 -susceptibility, confirming the critical role of these residues. We also tested additional three substitutions with bMF1 residues in α and γ subunits that further enhanced the IF1 -susceptibility, suggesting the additive role of these residues. We discuss the molecular mechanism by which IF1 specifically recognizes F1 with mitochondrial origin, based on the present result and the structure of F1 -IF1 complex. These findings would help the development of the inhibitors targeting bacterial F1 .

UI MeSH Term Description Entries

Related Publications

Yuichiro C Hatasaki, and Ryohei Kobayashi, and Ryo R Watanabe, and Mayu Hara, and Hiroshi Ueno, and Hiroyuki Noji
September 2000, The Journal of biological chemistry,
Yuichiro C Hatasaki, and Ryohei Kobayashi, and Ryo R Watanabe, and Mayu Hara, and Hiroshi Ueno, and Hiroyuki Noji
October 1997, The Biochemical journal,
Yuichiro C Hatasaki, and Ryohei Kobayashi, and Ryo R Watanabe, and Mayu Hara, and Hiroshi Ueno, and Hiroyuki Noji
September 2003, Nature structural biology,
Yuichiro C Hatasaki, and Ryohei Kobayashi, and Ryo R Watanabe, and Mayu Hara, and Hiroshi Ueno, and Hiroyuki Noji
August 2000, The Journal of biological chemistry,
Yuichiro C Hatasaki, and Ryohei Kobayashi, and Ryo R Watanabe, and Mayu Hara, and Hiroshi Ueno, and Hiroyuki Noji
September 2014, British journal of pharmacology,
Yuichiro C Hatasaki, and Ryohei Kobayashi, and Ryo R Watanabe, and Mayu Hara, and Hiroshi Ueno, and Hiroyuki Noji
August 2007, FEMS yeast research,
Yuichiro C Hatasaki, and Ryohei Kobayashi, and Ryo R Watanabe, and Mayu Hara, and Hiroshi Ueno, and Hiroyuki Noji
July 1993, European journal of biochemistry,
Yuichiro C Hatasaki, and Ryohei Kobayashi, and Ryo R Watanabe, and Mayu Hara, and Hiroshi Ueno, and Hiroyuki Noji
January 2016, PeerJ,
Yuichiro C Hatasaki, and Ryohei Kobayashi, and Ryo R Watanabe, and Mayu Hara, and Hiroshi Ueno, and Hiroyuki Noji
January 2022, Frontiers in physiology,
Yuichiro C Hatasaki, and Ryohei Kobayashi, and Ryo R Watanabe, and Mayu Hara, and Hiroshi Ueno, and Hiroyuki Noji
May 1988, Biochemical and biophysical research communications,
Copied contents to your clipboard!